Patents by Inventor Eric Calvosa
Eric Calvosa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240043826Abstract: Provided herein are methods of purifying messenger RNA (mRNA) by subjecting a preparation comprising in vitro synthesized mRNA to one or more steps of enzymatic digestion with a proteinase, optionally with a further oligo dT affinity chromatography step. Also provided are mRNA purified by the methods described herein.Type: ApplicationFiled: July 28, 2023Publication date: February 8, 2024Inventors: Eric CALVOSA, Nicolas CHAUDET, Arthur LECLERCQ, Alban LEPETITCOLIN
-
Patent number: 9750800Abstract: The subject of the invention is a method for purifying the rabies virus, comprising a single ion-exchange chromatography step, said step being cation exchange chromatography according to which: a) the supernatant of a culture of cells infected with this virus is brought into contact with a cation exchange chromatography support comprising a polymethacrylate matrix onto which sulfoisobutyl groups have been grafted such that the rabies virus binds to this support, and; b) the virus is eluted from its support.Type: GrantFiled: January 9, 2015Date of Patent: September 5, 2017Assignee: Sanofi Pasteur SAInventors: Virginie Fabre, Celine Rocca, Pierre Riffard, Eric Calvosa
-
Patent number: 9145543Abstract: The subject of the present invention is a process for producing adherent cells comprising: a. introducing a suspension of adherent cells into a culture vessel containing microcarriers in a culture medium; b. amplifying the cells by performing a plurality of cell passages in the same culture vessel wherein each cell passage subsequent to the first is carried out: i) by using all or part of the cells produced during the previous cell passage after having subjected the cells to enzyme treatment to detach the cells from the microcarriers, and ii) by introducing culture medium and an increasing amount of microcarriers into the culture medium; and c. harvesting the cells produced during the last cell passage, optionally after having subjected the cells to enzyme treatment to detach cells from microcarriers. The invention also relates to the implementation of this process for the production of biological agents, serving in particular to prepare vaccines or drugs.Type: GrantFiled: December 22, 2010Date of Patent: September 29, 2015Assignee: Sanofi Pasteur SAInventors: Eric Calvosa, Nicolas Seve
-
Publication number: 20150216963Abstract: The subject of the invention is a method for purifying the rabies virus, comprising a single ion-exchange chromatography step, said step being cation exchange chromatography according to which: a) the supernatant of a culture of cells infected with this virus is brought into contact with a cation exchange chromatography support comprising a polymethacrylate matrix onto which sulfoisobutyl groups have been grafted such that the rabies virus binds to this support, and; b) the virus is eluted from its support.Type: ApplicationFiled: January 9, 2015Publication date: August 6, 2015Applicant: Sanofi Pasteur SAInventors: Virginie Fabre, Celine Rocca, Pierre Riffard, Eric Calvosa
-
Patent number: 9028839Abstract: The invention relates to a vaccine composition comprising: a) inactivated whole virus, and b) a stabilizing excipient which comprises: i. a buffer solution, ii. a mixture of essential and nonessential amino acids, iii. a disaccharide, iv. a polyol, v. a chelating agent, vi. urea or a urea derivative, and vii. a nonionic surfactant.Type: GrantFiled: October 8, 2013Date of Patent: May 12, 2015Assignee: Sanofi Pasteur S.A.Inventors: Alain Francon, Michel Chevalier, Nadege Moreno, Eric Calvosa, Sandrine Cigarini, Virginie Fabre
-
Patent number: 8961997Abstract: The subject of the invention is a method for purifying the rabies virus, comprising a single ion-exchange chromatography step, said step being cation exchange chromatography according to which: a) the supernatant of a culture of cells infected with this virus is brought into contact with a cation exchange chromatography support comprising a polymethacrylate matrix onto which sulfoisobutyl groups have been grafted such that the rabies virus binds to this support, and; b) the virus is eluted from its support.Type: GrantFiled: April 8, 2010Date of Patent: February 24, 2015Assignee: Sanofi Pasteur SAInventors: Virginie Fabre, Céline Rocca, Pierre Riffard, Eric Calvosa
-
Publication number: 20140037684Abstract: The invention relates to a vaccine composition comprising: a) inactivated whole virus, and b) a stabilizing excipient which comprises: i. a buffer solution, ii. a mixture of essential and nonessential amino acids, iii. a disaccharide, iv. a polyol, v. a chelating agent, vi. urea or a urea derivative, and vii. a nonionic surfactant.Type: ApplicationFiled: October 8, 2013Publication date: February 6, 2014Applicant: Sanofi PasteurInventors: Alain Francon, Michel Chevalier, Nadege Moreno, Eric Calvosa, Sandrine Cigarini, Virginie Fabre
-
Patent number: 8557253Abstract: The invention relates to a vaccine composition comprising: a) inactivated whole virus, and b) a stabilizing excipient which comprises: i. a buffer solution, ii. a mixture of essential and nonessential amino acids, iii. a disaccharide, iv. a polyol, v. a chelating agent, vi. urea or a urea derivative, and vii. a nonionic surfactant.Type: GrantFiled: October 6, 2010Date of Patent: October 15, 2013Assignee: Sanofi Pasteur SAInventors: Alain Francon, Michel Chevalier, Nadege Moreno, Eric Calvosa, Sandrine Cigarini, Virginie Fabre
-
Publication number: 20110151506Abstract: The subject of the present invention is a process for producing adherent cells comprising: a. introducing a suspension of adherent cells into a culture vessel containing microcarriers in a culture medium; b. amplifying the cells by performing a plurality of cell passages in the same culture vessel wherein each cell passage subsequent to the first is carried out: i) by using all or part of the cells produced during the previous cell passage after having subjected the cells to enzyme treatment to detach the cells from the microcarriers, and ii) by introducing culture medium and an increasing amount of microcarriers into the culture medium; and c. harvesting the cells produced during the last cell passage, optionally after having subjected the cells to enzyme treatment to detach cells from microcarriers. The invention also relates to the implementation of this process for the production of biological agents, serving in particular to prepare vaccines or drugs.Type: ApplicationFiled: December 22, 2010Publication date: June 23, 2011Applicant: SANOFI PASTEUR SAInventors: Eric Calvosa, Nicolas Seve
-
Publication number: 20110081380Abstract: The invention relates to a vaccine composition comprising: a) inactivated whole virus, and b) a stabilizing excipient which comprises: i. a buffer solution, ii. a mixture of essential and nonessential amino acids, iii. a disaccharide, iv. a polyol, v. a chelating agent, vi. urea or a urea derivative, and vii. a nonionic surfactant.Type: ApplicationFiled: October 6, 2010Publication date: April 7, 2011Applicant: SANOFI PASTEURInventors: Alain Françon, Michel Chevalier, Nadège Moreno, Eric Calvosa, Sandrine Cigarini, Virginie Fabre
-
Publication number: 20100260798Abstract: The subject of the invention is a method for purifying the rabies virus, comprising a single ion-exchange chromatography step, said step being cation exchange chromatography according to which: a) the supernatant of a culture of cells infected with this virus is brought into contact with a cation exchange chromatography support comprising a polymethacrylate matrix onto which sulfoisobutyl groups have been grafted such that the rabies virus binds to this support, and; b) the virus is eluted from its support.Type: ApplicationFiled: April 8, 2010Publication date: October 14, 2010Applicant: SANOFI PASTEURInventors: Virginie Fabre, Céline Rocca, Pierre Riffard, Eric Calvosa